Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Maintenance of response with long-acting injectable risperidone in schizophrenia or schizoaffective disorder
2004-000830-35Phase 3Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Mar 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of risperidone in schizophrenia and schizoaffective disorder, sponsored by Janssen Pharmaceutical. Started Mar 2005; status: completed.
02
Drugs
risperidone
03
Conditions
schizophreniaschizoaffective disorder
Beyond the preview
Go deeper on 2004-000830-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-000830-35.